Patients taking Tysabri report improvement in physical and psychological well-being over time
Düsseldorf, Germany -- Sept. 11, 2009 -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced six-month results of an ongoing, one-year longitudinal, observational, patient-reported outcomes study showing multiple sclerosis (MS) patients taking TYSABRI® (natalizumab) experienced an improvement in both their physical function and psychological well-being.
Sep 11, 2009